The effectiveness of anti-IL5 biologics is comparable in previous-smokers and never-smokers with severe asthma Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021
Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017
Efficacy and safety of bupropion for the treatment of smoking cessation in patients with chronic bronchitis Source: Eur Respir J 2004; 24: Suppl. 48, 503s Year: 2004
Comparative effectiveness of two different doses of inhaled corticosteroid in triple therapy on exacerbations in patients with severe COPD: a real-world study Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19 Year: 2021
Do symptomatic asthmatic smokers need a higher maintenance dose when treated with budesonide/formoterol maintenance and reliever therapy than non-smokers? Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010
Physicians judge add-on omalizumab therapy as an effective treatment for patients with severe persistent allergic asthma: a pooled analysis Source: Eur Respir J 2005; 26: Suppl. 49, 49s Year: 2005
Efficacy of roflumilast in former and current smokers with COPD Source: Annual Congress 2011 - COPD management Year: 2011
Restoring corticosteroid sensitivity in COPD and smokers with asthma Source: Annual Congress 2008 - Smokers with asthma versus COPD: differences and similarities Year: 2008
Cost-effectiveness of early intervention with once-daily budesonide in children with mild persistent asthma: results from the START study Source: Eur Respir J 2003; 22: Suppl. 45, 34s Year: 2003
Patients with moderate asthma symptoms may benefit from short-term inhaled corticosteroid monotherapy Source: Eur Respir J 2007; 30: Suppl. 51, 615s Year: 2007
Can smoking asthmatic subjects benefit from anti-asthmatic treatment? Source: Eur Respir J 2007; 30: Suppl. 51, 15s Year: 2007
The efficacy of omalizumab in severe in asthma after treatment withdrawal Source: Annual Congress 2009 - Towards improving asthma control Year: 2009
Efficacy of montelukast in Indian patients having chronic persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 372s Year: 2003
Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma Year: 2012
Adding omalizumab to high-dose ICS and LABA significantly improves quality of life in patients with severe persistent allergic asthma Source: Eur Respir J 2006; 28: Suppl. 50, 440s Year: 2006
The cost-efficacy of combined anti-inflammatory therapy in the treatment of children in severe persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 134s Year: 2003
Comparison of the efficacy of cicleosonide with budesonide in mild to moderate asthma patients after step-down therapy Source: Annual Congress 2011 - Asthma management and response Year: 2011
Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005
Efficacy of long-term formoterol therapy vs as-needed salbutamol use in patients with moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 426s Year: 2001